GXLV.L vs. BTEK.L
GXLV.L (SPDR S&P US Health Care Select Sector UCITS ETF) and BTEK.L (iShares Nasdaq US Biotechnology UCITS ETF) are both Health & Biotech Equities funds - GXLV.L tracks the MSCI World/Health Care NR USD while BTEK.L tracks the NASDAQ Biotechnology TR USD. Both are passively managed. Over the past 3 years, GXLV.L returned 3.78%/yr vs 10.19%/yr for BTEK.L. At a 0.32 correlation, their price movements are largely independent. GXLV.L charges 0.15%/yr vs 0.35%/yr for BTEK.L.
Performance
GXLV.L vs. BTEK.L - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, GXLV.L achieves a -1.77% return, which is significantly lower than BTEK.L's 4.86% return.
GXLV.L
- 1D
- 2.97%
- 1M
- 5.54%
- YTD
- -1.77%
- 6M
- -1.34%
- 1Y
- 16.55%
- 3Y*
- 3.78%
- 5Y*
- —
- 10Y*
- —
BTEK.L
- 1D
- 3.56%
- 1M
- 0.78%
- YTD
- 4.86%
- 6M
- 3.27%
- 1Y
- 43.50%
- 3Y*
- 10.19%
- 5Y*
- 5.85%
- 10Y*
- —
GXLV.L vs. BTEK.L - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|---|
GXLV.L SPDR S&P US Health Care Select Sector UCITS ETF | -1.77% | 6.82% | 3.59% | -3.78% | 7.82% |
BTEK.L iShares Nasdaq US Biotechnology UCITS ETF | 4.86% | 23.81% | -0.32% | 0.33% | 5.40% |
Correlation
The correlation between GXLV.L and BTEK.L is 0.41, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.41 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.32 |
Correlation (All Time) Calculated using the full available price history since Apr 6, 2022 | 0.32 |
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
GXLV.L vs. BTEK.L — Risk / Return Rank
GXLV.L
BTEK.L
GXLV.L vs. BTEK.L - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for SPDR S&P US Health Care Select Sector UCITS ETF (GXLV.L) and iShares Nasdaq US Biotechnology UCITS ETF (BTEK.L). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| GXLV.L | BTEK.L | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -0.91 | ||
| Sortino ratioReturn per unit of downside risk | -1.09 | ||
| Omega ratioGain probability vs. loss probability | 1.24 | 1.38 | -0.14 |
| Calmar ratioReturn relative to maximum drawdown | 2.16 | 6.23 | -4.08 |
| Martin ratioReturn relative to average drawdown | 4.76 | 17.55 | -12.80 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading charts...
Sharpe Ratios by Period
| GXLV.L | BTEK.L | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 1.34 | 2.24 | -0.91 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | — | 0.29 | — |
Sharpe Ratio (All Time)Calculated using the full available price history | 0.31 | 0.31 | +0.01 |
Drawdowns
GXLV.L vs. BTEK.L - Drawdown Comparison
The maximum GXLV.L drawdown since its inception was -19.59%, smaller than the maximum BTEK.L drawdown of -30.86%. Use the drawdown chart below to compare losses from any high point for GXLV.L and BTEK.L.
Loading charts...
Drawdown Indicators
| GXLV.L | BTEK.L | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -19.59% | -30.86% | +11.27% |
Max Drawdown (1Y)Largest decline over 1 year | -11.51% | -6.89% | -4.62% |
Max Drawdown (3Y)Largest decline over 3 years | -19.59% | -26.34% | +6.75% |
Max Drawdown (5Y)Largest decline over 5 years | — | -30.86% | — |
Current DrawdownCurrent decline from peak | -5.07% | -1.86% | -3.21% |
Average DrawdownAverage peak-to-trough decline | -6.15% | -10.04% | +3.89% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 9.07% | 2.45% | +6.62% |
Volatility
GXLV.L vs. BTEK.L - Volatility Comparison
The current volatility for SPDR S&P US Health Care Select Sector UCITS ETF (GXLV.L) is 5.53%, while iShares Nasdaq US Biotechnology UCITS ETF (BTEK.L) has a volatility of 6.91%. This indicates that GXLV.L experiences smaller price fluctuations and is considered to be less risky than BTEK.L based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| GXLV.L | BTEK.L | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 5.53% | 6.91% | -1.38% |
Volatility (6M)Calculated over the trailing 6-month period | 12.37% | 14.67% | -2.30% |
Volatility (1Y)Calculated over the trailing 1-year period | 18.62% | 19.14% | -0.52% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 20.60% | 20.08% | +0.52% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 20.60% | 21.71% | -1.11% |
GXLV.L vs. BTEK.L - Expense Ratio Comparison
GXLV.L has a 0.15% expense ratio, which is lower than BTEK.L's 0.35% expense ratio.
Dividends
GXLV.L vs. BTEK.L - Dividend Comparison
Neither GXLV.L nor BTEK.L has paid dividends to shareholders.
Frequently Asked Questions
GXLV.L and BTEK.L have a correlation of 0.41, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
On fees, GXLV.L is cheaper at 0.15% per year. The better choice depends on whether you care most about return, fees, risk, or income.
GXLV.L is cheaper with a 0.15% expense ratio, compared with 0.35% for BTEK.L.
GXLV.L tracks MSCI World/Health Care NR USD, while BTEK.L tracks NASDAQ Biotechnology TR USD. They also come from different issuers: State Street and iShares. Their fees differ too: 0.15% for GXLV.L and 0.35% for BTEK.L.
Find the right allocation for GXLV.L and BTEK.L
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer